Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, USA.
Expert Rev Endocrinol Metab. 2024 Jan-May;19(1):11-20. doi: 10.1080/17446651.2023.2279533. Epub 2024 Jan 1.
This review highlights the pathogenesis of both microvascular and macrovascular complications of diabetes and how these mechanisms influence both the management and preventative strategies of these complications. The cumulative data shown in this review suggest hyperglycemic and blood pressure control remain central to this intricate process.
We reviewed the literature including retrospective, prospective trials as well as meta-analysis, and post hoc analysis of randomized trials on microvascular andmacrovascular complications.
Further research is needed to explore the ideal intervention targets and preventative strategies needed to prevent macrovascular complications. Furthermore, as the data for trials looking at microvascular complications lengthen more long-term data will further elucidate the role that the duration of diabetes has on these complications. Additionally, trials looking to maximize hyperglycemic control with multiple agents in diabetes, such as metformin, SGL2isand GLP-1 receptor agonists are currently in process, which will have implications for rates of microvascular as well as macrovascular complications.
本综述强调了糖尿病微血管和大血管并发症的发病机制,以及这些机制如何影响这些并发症的管理和预防策略。本综述中显示的累积数据表明,高血糖和血压控制仍然是这一复杂过程的核心。
我们回顾了文献,包括回顾性、前瞻性试验以及荟萃分析和随机试验的事后分析,涉及微血管和大血管并发症。
需要进一步研究以探索预防大血管并发症所需的理想干预目标和预防策略。此外,随着研究微血管并发症的试验数据的延长,更多的长期数据将进一步阐明糖尿病持续时间对这些并发症的影响。此外,目前正在进行旨在使用多种药物(如二甲双胍、SGLT2is 和 GLP-1 受体激动剂)最大限度地控制高血糖的试验,这将对微血管和大血管并发症的发生率产生影响。